Be Prepared to Dispense Alternatives to Usual COVID-19 Meds
October 2021
Shortages of tocilizumab (Actemra) mean you'll see more orders for other COVID-19 treatments.
Tocilizumab has been the go-to add-on to steroids (dexamethasone, etc) for COVID-19. It's because this "IL-6 inhibitor" has the strongest evidence for reducing mortality.
But tocilizumab supplies are low. And it may need to be reserved for other uses where tocilizumab is the only treatment.
Practical advice for a better career, with unlimited access to CE
Pharmacy Technician's Letter includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 120+ CE courses, including the popular CE-in-the-Letter
- Helpful, in-depth Technician Tutorials
- Access to the entire archive
Already a subscriber? Log in
Volume pricing available. Get a quote